Abstract 451P
Background
Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. To reduce the risk of an infusion-related reaction (IRR) with ramucirumab, H1-antihistamines are recommended as premedication. However, IRR is hardly observed in clinical practice in the ramucirumab regimen. The H1-antihistamines have several side effects, such as drowsiness and dizziness, and the use of H1-antihistamines might be restricted for the patients who need to drive a car or for elderly patients. The aim of this study was to investigate the safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancer.
Methods
We retrospectively reviewed the solid tumour patients who received ramucirumab, including regimen without H1-antihistamines at our institution between 2017 and 2019. The patients who received antiemetic steroid for cytotoxic chemotherapy was also included. The primary endpoint was the incidence of IRR during the infusion in the first cycle. The secondary endpoints were the incidence of IRR at any time and other ramucirumab related adverse events.
Results
Of the 51 patients enrolled (median age, 69.5 years; range 41 - 83), 28 (55%) were male. The origins of cancer were gastric cancer (n = 22), lung cancer (n = 26), and colon cancer (n = 3), respectively. Forty-two patients (82%) received ramucirumab in combination with antiemetic steroid for cytotoxic chemotherapy, and nine patients (18%) received ramucirumab monotherapy without steroid. No IRR was observed in this study (IRR rate, 0%; 95% CI 0 - 0.69). Among the overall 272 infusions, there were no events of IRRs or other ramucirumab related adverse events.
Conclusions
There was no IRRs without H1-antihistamines in our retrospective study. Ramucirumab without H1-antihistamines as premedication would be a favourable option for the patients who had trouble with the side effects of H1 antihistamine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract